# ProstACT SELECT (NCT04786847)

> 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

No report yet. It can be ordered.

- Drugs tested: 177Lu-DOTA-TLX591
- Indication: PSMA-expressing metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04786847
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
- Conditions: Metastatic Prostate Cancer
- Interventions: 177Lu-DOTA-TLX591
- Enrollment: 30
- Primary outcome: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

## Indexed commentary on ProstACT SELECT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=prostact-select-nct04786847